Local Prescribing Information (Oncology):

 

Atezolizumab Injection [Tecentriq®]

Bevacizumab Injection [Avastin® and Syndyma®]

Obinutuzumab Injection [Gazyva®]

Trastuzumab for Injection [Herclon™ and Biceltis®]

Trastuzumab emtansine for Injection [Kadcyla®]

Pertuzumab Injection [Perjeta®]

Rituximab Injection [Ristova® and Ikgdar®]

Alectinib Capsules [Alecensa®]

Erlotinib Tablets I.P. [Tarceva®]

Capecitabine Tablets I.P. [Xeloda®]

 

 

Safety Update Information for Healthcare Professionals (Oncology):

 

DIL and DHPC package issued for Tecentriq regarding SCARs (Severe Cutaneous Adverse Reactions) s an Identified Risk dated 6th Nov 2020

5-Fluorouracil (i.v.), Capecitabine and Tegafur containing products Pre-treatment testing to identify DPDdeficient patients at increased risk of severe toxicity dated 19th May 2020

DHPC Tecetriq Atezolizumab Injection 1200mg20ml Safety Update Identified risk -Immune-related myositis dated 31st January 2019

DHCP Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018

DHPC Tecentriq Atezolizumab Injection 1200mg20ml Important Identified risk immune related nephritis dated 30th July, 2018

DHCP Tecentriq Atezolizumab Injection 1200MG..20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018